Drug Trial Radar · NCT05269004
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,300
Planned (sponsor's estimate)
Start
May 3, 2022
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study. Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.
Conditions
- Multiple Sclerosis
Interventions
OcrelizumabDrug
Ocrelizumab will be administered based on the dosage and administration received at the time of rollover from the Parent study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events, with severity determined according to the NCI CTCAE v5.0Time frame: Up to 44 months
Locations
232 sites in 37 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
Arizona Neuroscience Research LLC
Phoenix, Arizona
MS Center of California
Laguna Hills, California
Stanford Hospital and Clinics
Palo Alto, California
University of California San Francisco
San Francisco, California
University of California San Francisco
San Francisco, California
University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center)
Aurora, Colorado
Advanced Neurosciences Research LLC
Fort Collins, Colorado
Neurology Associates PA
Maitland, Florida
University of Miami
Miami, Florida
Neurological Services of Orlando
Orlando, Florida
University of South Florida
Tampa, Florida
Vero Beach Neurology and Research Institute
Vero Beach, Florida
Atlanta Neuroscience Institute
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Consultants in Neurology Ltd
Northbrook, Illinois
Indiana Univ School of Med
Indianapolis, Indiana
Kansas University Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Boston, Massachusetts
Wayne State University
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
Michigan Institute for Neurological Disorders
Farmington Hills, Michigan
Minneapolis Clinic of Neurology
Golden Valley, Minnesota
Washington University
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Rutgers New Jersey Medical School Department of Neurology
Newark, New Jersey
Holy Name Hospital
Teaneck, New Jersey
University of New Mexico
Albuquerque, New Mexico
SUNY at Stony Brook
Stony Brook, New York
OnSite Clinical Solutions LLC
Charlotte, North Carolina
The Neurological Institute PA
Charlotte, North Carolina
Atrium Health
Charlotte, North Carolina
Raleigh Neurology Associates
Raleigh, North Carolina
University Neurology Inc.
Cincinnati, Ohio
Columbus Neuroscience
Westerville, Ohio
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma
Providence Neurological Specialties
Portland, Oregon
Abington Neurological Associates
Abington, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Neurology Clinic PC
Cordova, Tennessee
Showing 40 of 232 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.